HK1082918A1 - Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis - Google Patents

Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis

Info

Publication number
HK1082918A1
HK1082918A1 HK06102877A HK06102877A HK1082918A1 HK 1082918 A1 HK1082918 A1 HK 1082918A1 HK 06102877 A HK06102877 A HK 06102877A HK 06102877 A HK06102877 A HK 06102877A HK 1082918 A1 HK1082918 A1 HK 1082918A1
Authority
HK
Hong Kong
Prior art keywords
oestrogen
progestin
endometriosis
treatment
combination
Prior art date
Application number
HK06102877A
Other languages
English (en)
Inventor
Stephen Rubin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1082918A1 publication Critical patent/HK1082918A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK06102877A 2003-02-05 2006-03-06 Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis HK1082918A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0302572.3A GB0302572D0 (en) 2003-02-05 2003-02-05 Method of treatment
PCT/GB2004/000414 WO2004069260A1 (en) 2003-02-05 2004-02-03 Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
HK1082918A1 true HK1082918A1 (en) 2006-06-23

Family

ID=9952433

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06102877A HK1082918A1 (en) 2003-02-05 2006-03-06 Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis

Country Status (30)

Country Link
US (2) US7910570B2 (xx)
EP (2) EP1857111A3 (xx)
JP (2) JP4658918B2 (xx)
KR (1) KR101075929B1 (xx)
CN (1) CN100393360C (xx)
AR (1) AR043013A1 (xx)
AT (1) ATE374612T1 (xx)
AU (1) AU2004210184B2 (xx)
BR (1) BRPI0407039A (xx)
CA (1) CA2513910C (xx)
CO (1) CO5580789A2 (xx)
CY (1) CY1107816T1 (xx)
DE (1) DE602004009288T2 (xx)
DK (1) DK1589976T3 (xx)
ES (1) ES2293215T3 (xx)
GB (1) GB0302572D0 (xx)
HK (1) HK1082918A1 (xx)
IL (1) IL169583A0 (xx)
IS (1) IS2547B (xx)
MX (1) MXPA05008347A (xx)
MY (1) MY140723A (xx)
NO (1) NO20053626L (xx)
NZ (1) NZ541222A (xx)
PL (1) PL214680B1 (xx)
PT (1) PT1589976E (xx)
RU (2) RU2360681C2 (xx)
TW (1) TWI354556B (xx)
UA (1) UA80741C2 (xx)
WO (1) WO2004069260A1 (xx)
ZA (1) ZA200506221B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
JP2008515810A (ja) * 2004-10-04 2008-05-15 ウェイン ステイト ユニヴァーシティ 子宮内膜腔および子宮に対する外科的処置の準備における子宮内膜菲薄化のためのアロマターゼ阻害剤の使用
WO2009075838A2 (en) * 2007-12-10 2009-06-18 Meditrina Pharmaceuticals, Inc. Treatment of menorrhagia with aromatase inhibitor
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
RU2541089C1 (ru) * 2013-11-22 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательски институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Способ комплексного лечения наружного генитального эндометриоза
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
KR20240076617A (ko) 2022-11-22 2024-05-30 성균관대학교산학협력단 디프레닐로로볼을 유효성분으로 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물
WO2024197239A1 (en) * 2023-03-23 2024-09-26 William Bologna Bioadhesive compositions and a method of treating endometriosis with aromatase inhibitors without increased gonadatroprin production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
WO1990010462A1 (en) * 1989-03-10 1990-09-20 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
JP2602456B2 (ja) 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
TR200102867T2 (xx) 1998-06-11 2002-06-21 Endorecherchel@Inc
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US20040192598A1 (en) 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
CA2434611A1 (en) 2001-01-26 2002-09-19 Pharmacia Italia Spa Combined method for treating hormono-dependent disorders
WO2002074315A1 (de) 2001-03-21 2002-09-26 Schering Aktiengesellschaft Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017973A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
WO2003039455A2 (en) 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Methods of treating endometreosis
CA2472240A1 (en) 2002-01-22 2003-07-31 Akzo Nobel N.V. Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
WO2003082299A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Improved hormone replacement therapy
WO2003082336A1 (en) 2002-04-03 2003-10-09 Jencap Research Ltd. Female birth control method
US20040235812A1 (en) 2002-04-03 2004-11-25 Caspers Robert F Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
EP1578930A4 (en) * 2002-06-27 2008-07-02 Centocor Inc CNGH0004 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
AR043013A1 (es) 2005-07-13
AU2004210184A1 (en) 2004-08-19
RU2008138166A (ru) 2010-03-27
EP1589976B1 (en) 2007-10-03
RU2005127667A (ru) 2006-03-27
TW200503731A (en) 2005-02-01
US20110009373A1 (en) 2011-01-13
PL377939A1 (pl) 2006-02-20
RU2360681C2 (ru) 2009-07-10
PL214680B1 (pl) 2013-09-30
CN1747736A (zh) 2006-03-15
IS2547B (is) 2009-10-15
US20060142256A1 (en) 2006-06-29
KR20050098296A (ko) 2005-10-11
MXPA05008347A (es) 2005-11-04
TWI354556B (en) 2011-12-21
NZ541222A (en) 2008-12-24
GB0302572D0 (en) 2003-03-12
CN100393360C (zh) 2008-06-11
CO5580789A2 (es) 2005-11-30
IS8008A (is) 2005-08-30
EP1589976A1 (en) 2005-11-02
DK1589976T3 (da) 2007-12-27
CA2513910C (en) 2012-04-03
EP1857111A2 (en) 2007-11-21
ES2293215T3 (es) 2008-03-16
WO2004069260A1 (en) 2004-08-19
US7910570B2 (en) 2011-03-22
KR101075929B1 (ko) 2011-10-26
IL169583A0 (en) 2007-07-04
ATE374612T1 (de) 2007-10-15
ZA200506221B (en) 2006-05-31
BRPI0407039A (pt) 2006-01-17
JP2006516602A (ja) 2006-07-06
AU2004210184B2 (en) 2007-01-04
DE602004009288T2 (de) 2008-07-10
EP1857111A3 (en) 2009-03-04
DE602004009288D1 (de) 2007-11-15
JP4658918B2 (ja) 2011-03-23
CA2513910A1 (en) 2004-08-19
PT1589976E (pt) 2007-11-22
UA80741C2 (en) 2007-10-25
JP2011001388A (ja) 2011-01-06
MY140723A (en) 2010-01-15
CY1107816T1 (el) 2013-06-19
NO20053626L (no) 2005-08-26

Similar Documents

Publication Publication Date Title
HK1082918A1 (en) Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis
IL175858A0 (en) Extended use combination comprising estrogens and progestins
HK1095529A1 (en) Methods for the treatment of endometriosis
HK1100411A1 (en) Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
AP2004003192A0 (en) Combination of azelastine and steroids.
HK1074987A1 (en) Medical device package, kit and associated methods
PL1625343T3 (pl) Elastyczny pakiet odporny na penetrację i jego zastosowanie
AP2007003960A0 (en) Indazoles, benzisoxazoles and benzisothiazoles andtheir use as estrogenic agents
IL173188A0 (en) Use of alcohol-oxyalkyates in the form of adjuvants for benzamidoxime gungicidal derivatives, appropriate agents and kits
SI1589976T1 (sl) Uporaba kombinacije aromataznega inhibitorja, progestina in estrogena za zdravljenje endometrioze
EP1765990A4 (en) THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS FOR HEPATITIS B
EP1603535A4 (en) AROMATASE HEMMER DIAGNOSIS AND THERAPY
GB2386374B (en) Slipping agent
AU2002350362A8 (en) Use of an anti-microtubule agent for the treatment of uveitis
EE200300505A (et) Aromataasi inhibiitori kasutamine ravimi valmistamiseks viljatuse raviks
EP1510796A4 (en) COMBINATIONAL OPERATING PROCEDURE AND COMBINATION SCALE
HK1099689A1 (en) Combination of a heterocyclic compound and an antioxidant and use thereof for the manufacture of a medicament for treating obesity
EP1638573A4 (en) USE OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS
EP1648469A4 (en) ANTIGLUCOCORTICOIDES FOR THE TREATMENT OF CATATONIA
GB0400659D0 (en) Microprocessor, related method of operating the same and related instruction word
IL175050A0 (en) Fungicidal mixtures for the prevention of rice pathogens
GB0317272D0 (en) Strap on penis
GB0323792D0 (en) Body wrap
GB0328826D0 (en) Body wrap
GB0228976D0 (en) Body Wrap

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150203